Table of Contents

List of contributors vii

Preface ix

1 Non-alcoholic fatty liver disease: Hype or harm? 3
Stephen H. Caldwell and Curtis K. Argo

2 NAFLD: A worldwide problem 8
Joanna K. Dowman, Geoffrey C. Farrell, and Philip Newsome

3 Is insulin resistance the principal cause of NAFLD? 15
Ian F. Godsland, Sanjeev Mehta, Shareen Forbes, Fabian Meienberg, Michael Yee, Simon D. Taylor-Robinson, and Desmond G. Johnston

4 Paediatric NAFLD: A distinct disease with the propensity for progressive fibrosis 29
Emer Fitzpatrick and Anil Dhawan

5 Non-alcoholic fatty liver disease (NAFLD) as cause of cryptogenic cirrhosis 36
Jay H. Lefkowitch

6 Is NAFLD different in absence of metabolic syndrome? 44
Yusuf Yilmaz

7 Occurrence of noncirrhotic HCC in NAFLD 50
Dawn M. Torres and Stephen A. Harrison Part II: Factors in Disease Progression

8 Fibrosis progression: Putative mechanisms and molecular pathways 61
Wing-Kin Syn and Anna Mae Diehl

9 When is it NAFLD and when is it ALD?: Can the histologic evaluation of a liver biopsy guide the clinical evaluation? 72
Elizabeth M. Brunt and David E. Kleiner

10 Of men and microbes: Role of the intestinal microbiome in non-alcoholic fatty liver disease 82
Muhammad Bilal Siddiqui, Mohammed Shadab Siddiqui, and Arun J. Sanyal

11 Can genetic influence in non-alcoholic fatty liver disease be ignored? 91
Yang-Lin Liu, Christopher P. Day, and Quentin M. Anstee

12 Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events? 103
Soo Lim Part III: Diagnosis and Scoring

13 How to best diagnose NAFLD/NASH? 113
Vlad Ratziu

14 The clinical utility of noninvasive blood tests and elastography 124
Emmanuel A. Tsochatzis and Massimo Pinzani

15 Are the guidelines-AASLD, IASL, EASL, and BSG-of help in the management of patients with NAFLD? 131
Cristina Margini and Jean-Francois Dufour

16 Imaging methods for screening of hepatic steatosis 138
Hero K. Hussain

17 Are the advantages of obtaining a liver biopsy outweighed by the disadvantages? 152
Jeremy F. L. Cobbold and Simon D. Taylor-Robinson

18 Screening for NAFLD in high-risk populations 161
Nader Lessan Part IV: Value of treatment measures

19 Defining the role of metabolic physician 173
Nicholas Finer

20 Should physicians be prescribing or patients self-medicating with orlistat, vitamin E, vitamin D, insulin sensitizers, pentoxifylline, or coffee? 182
Haripriya Maddur and Brent A. Neuschwander-Tetri

21 Effects of treatment of NAFLD on the metabolic syndrome 189
Hannele Yki-Jarvinen

22 What are the dangers as well as the true benefits of bariatric surgery? 196
Andrew Jenkinson

23 Liver transplantation: What can it offer? 203
Roger Williams Part V: What does the future hold?

24 Molecular antagonists, leptin or other hormones in supplementing environmental factors? 211
Jonathan M. Hazlehurst and Jeremy W. Tomlinson

25 What is the role of antifibrotic therapies in the current and future management of NAFLD? 218
Natasha McDonald and Jonathan Fallowfield

26 Developmental programming of non-alcoholic fatty liver disease 226
Jiawei Li, Paul Cordero, and Jude A. Oben

Index 232

About the Author

Professor Roger Williams CBE, runs the Institute of Hepatology at UCL, and is a twice former president of EASL. He has authored an incredible 2100 journal articles. Despite advancing years, he is still actively involved in clinical research -- 340 articles in the past ten years, and analysis by ISI shows him to be one of the most influential researchers in his field. The award of a CBE for services to medicine recognised his major contribution to the study of liver disorders over 25 years including leading the team who performed the first ever UK liver transplant. He also performed George Best's controversial liver transplant in 2002.
Prof Williams has had many awards, medals, honorary fellowships, and in 2006 was included by HRH The Queen in a celebration at Buckingham Palace to honour those who continue to contribute to public service beyond the age of 65yrs. He was made a Fellow of King's College London in 1992 and an Honorary Fellowship from UCL was conferred on him in 2008, in recognition of his distinguished career and outstanding service to UCL.Professor Simon Taylor-Robinson joined the Department of Medicine at Imperial College London in 1997, having previously been Senior Registrar in Gastroenterology and Hepatology at Hammersmith Hospital. He was awarded the Sir Francis Avery Jones Gold Medal by the British Society of Gastroenterology in 1999 and the Young Investigator Award of the Liver Section of the European Gastroenterology Association in 1997. He is currently Director of the Imperial Clinical Research Facility at St Mary's Hospital, London.